95 related articles for article (PubMed ID: 18033308)
1. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.
Finocchiaro LM; Glikin GC
Gene Ther; 2008 Feb; 15(4):267-76. PubMed ID: 18033308
[TBL] [Abstract][Full Text] [Related]
2. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma.
Finocchiaro LM; Fiszman GL; Karara AL; Glikin GC
Cancer Gene Ther; 2008 Mar; 15(3):165-72. PubMed ID: 18219342
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.
Finocchiaro LM; Glikin GC
Cancer Gene Ther; 2012 Dec; 19(12):852-61. PubMed ID: 23059870
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas.
Finocchiaro LM; Villaverde MS; Gil-Cardeza ML; Riveros MD; Glikin GC
Res Vet Sci; 2011 Oct; 91(2):230-4. PubMed ID: 21300385
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.
Finocchiaro LM; Fondello C; Gil-Cardeza ML; Rossi ÚA; Villaverde MS; Riveros MD; Glikin GC
Hum Gene Ther; 2015 Jun; 26(6):367-76. PubMed ID: 25762364
[TBL] [Abstract][Full Text] [Related]
6. Combination of cytokine-enhanced vaccine and chemo-gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.
Finocchiaro LME; Agnetti L; Fondello C; Glikin GC
Gene Ther; 2019 Nov; 26(10-11):418-431. PubMed ID: 30858538
[TBL] [Abstract][Full Text] [Related]
7. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.
Dow SW; Elmslie RE; Willson AP; Roche L; Gorman C; Potter TA
J Clin Invest; 1998 Jun; 101(11):2406-14. PubMed ID: 9616212
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.
Quintin-Colonna F; Devauchelle P; Fradelizi D; Mourot B; Faure T; Kourilsky P; Roth C; Mehtali M
Gene Ther; 1996 Dec; 3(12):1104-12. PubMed ID: 8986437
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.
Pandha H; Eaton J; Greenhalgh R; Soars D; Dalgleish A
Cancer Gene Ther; 2005 Jun; 12(6):572-8. PubMed ID: 15803141
[TBL] [Abstract][Full Text] [Related]
12. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
13. Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting.
Villaverde MS; Combe K; Duchene AG; Wei MX; Glikin GC; Finocchiaro LM
Int Immunopharmacol; 2014 Sep; 22(1):167-75. PubMed ID: 24973616
[TBL] [Abstract][Full Text] [Related]
14. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
Bergman PJ; Camps-Palau MA; McKnight JA; Leibman NF; Craft DM; Leung C; Liao J; Riviere I; Sadelain M; Hohenhaus AE; Gregor P; Houghton AN; Perales MA; Wolchok JD
Vaccine; 2006 May; 24(21):4582-5. PubMed ID: 16188351
[TBL] [Abstract][Full Text] [Related]
15. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
[TBL] [Abstract][Full Text] [Related]
16. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
[TBL] [Abstract][Full Text] [Related]
17. Cytokine therapy in advanced melanoma.
Kalaaji AN
J Drugs Dermatol; 2007 Apr; 6(4):374-8. PubMed ID: 17668534
[TBL] [Abstract][Full Text] [Related]
18. Melanoma vaccines.
Naylor MF
Dermatol Online J; 2000 Sep; 6(1):5. PubMed ID: 11328615
[TBL] [Abstract][Full Text] [Related]
19. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells.
Sobotkova E; Duskova M; Eckschlager T; Vonka V
Int J Oncol; 2008 Aug; 33(2):421-6. PubMed ID: 18636165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
